Tisento Therapeutics
Bill Kissel is an accomplished pharmaceutical operations executive with extensive experience in the industry. Currently serving as Vice President of Pharmaceutical Operations at Tisento Therapeutics since August 2023, Bill has held several senior leadership roles, including Vice President and Head of Pharmaceutical Development at Cyclerion from April 2019 to July 2023 and various positions at Ironwood Pharmaceuticals from August 2007 to March 2019, such as Sr. Director of Chemical Development. Previous to that, Bill worked at Pfizer from May 1999 to June 2007 as a Sr. Principal Scientist. Bill holds a Postdoctoral degree in Chemistry from Emory University, a Ph.D. in Chemistry from Indiana University Bloomington, and a BS in Chemistry from the University of Illinois Urbana-Champaign.
This person is not in any teams
This person is not in any offices
Tisento Therapeutics
Ti sento means “I hear you" in Italian. At Tisento Therapeutics, we believe that meaningful innovation requires understanding the problem, and that starts with listening. First and foremost, we listen to those impacted by debilitating diseases to understand the daily challenges they face. We also listen to healthcare providers, patient advocates, regulatory agencies, and scientific data. All these inputs inform our thinking and shape how we conduct our research, design our trials, and evolve our company. We are on a mission to deliver medicines that address what matters most. Our lead candidate is zagociguat (formerly CY6463), a Phase 2, first-in-class, brain-penetrant sGC stimulator, which is advancing in MELAS and other genetic mitochondrial diseases. Zagociguat is ideally suited to treat mitochondrial diseases with both CNS and peripheral symptoms, such as cognitive impairment, fatigue, and muscle weakness.